Spots Global Cancer Trial Database for high risk prostate cancer
Every month we try and update this database with for high risk prostate cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Stereotactic Pelvic Brachytherapy With HDR Boost for Dose Escalation in High Tier Intermediate and High Risk Prostate ca | NCT04236752 | HIGH RISK PROST... | Stereotactic Ab... | 18 Years - | Sunnybrook Health Sciences Centre | |
| Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer | NCT05313815 | Prostate Cancer | Moderate hypofr... | 18 Years - | University Health Network, Toronto | |
| The Role of Tomotherapy in Hypofractionated/Dose Escalated Conformal Radiation Treatment for High Risk Prostate Cancer | NCT00126802 | Prostate Cancer | Tomotherapy | - 75 Years | AHS Cancer Control Alberta | |
| Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate | NCT02268175 | Prostate Adenoc... Prostate Cancer High Risk Prost... | Enzalutamide Abiraterone Ace... Prednisone Leuprolide Acet... | 18 Years - | Dana-Farber Cancer Institute | |
| Prostate Boost Irradiation With Stereotactic Body RT (SBRT) | NCT03380806 | Prostate Cancer | LHRH agonist Pelvic Radiatio... Stereotactic Bo... Conventional Ra... | 18 Years - 85 Years | Juravinski Cancer Center | |
| Safety and Efficacy Study of Hypofractionated Radiotherapy and Androgen Deprivation Therapy for Prostate Cancer | NCT01505075 | Prostate Cancer | Hypofractionate... | 18 Years - | Sunnybrook Health Sciences Centre | |
| Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate | NCT02268175 | Prostate Adenoc... Prostate Cancer High Risk Prost... | Enzalutamide Abiraterone Ace... Prednisone Leuprolide Acet... | 18 Years - | Dana-Farber Cancer Institute | |
| PROspective Multicenter Observational Study on Elective Pelvic Nodes Irradiation. | NCT03340272 | Intermediate Ri... High Risk Prost... | 18 Years - | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | ||
| FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer | NCT01439542 | Prostate Cancer | Stereotactic Bo... Luteinizing Hor... | 18 Years - | Lawson Health Research Institute | |
| Trial Comparing Radical Radiotherapy to Prostate Only VS Prostate And Pelvic Lymph Nodes in Intermediate And High Risk Prostate Cancer | NCT05285319 | Prostate Cancer | Prostate Only R... Prostate and Pe... | - | Cairo University | |
| Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate | NCT02268175 | Prostate Adenoc... Prostate Cancer High Risk Prost... | Enzalutamide Abiraterone Ace... Prednisone Leuprolide Acet... | 18 Years - | Dana-Farber Cancer Institute | |
| Prostate Boost Irradiation With Stereotactic Body RT (SBRT) | NCT03380806 | Prostate Cancer | LHRH agonist Pelvic Radiatio... Stereotactic Bo... Conventional Ra... | 18 Years - 85 Years | Juravinski Cancer Center | |
| Conventional Versus Hypofractionated Radiation in High Risk Prostate Patients | NCT01488968 | High-risk Prost... | Standard Radiat... Hypofractionate... | 18 Years - | AHS Cancer Control Alberta | |
| Dose Escalation Study of Preoperative SBRT for High Risk Prostate Cancer | NCT02572284 | Prostate Cancer | Stereotactic Bo... Prostatectomy Quality of Life... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Safety and Efficacy Study of Hypofractionated Radiotherapy and Androgen Deprivation Therapy for Prostate Cancer | NCT01505075 | Prostate Cancer | Hypofractionate... | 18 Years - | Sunnybrook Health Sciences Centre | |
| Hypofractionated Boost vs Conventionally Fractionated Boost for Localized High Risk Prostate Cancer | NCT03526510 | Prostate Cancer | Conventionally ... | 18 Years - | Sunnybrook Health Sciences Centre | |
| Dose Escalation Study of Preoperative SBRT for High Risk Prostate Cancer | NCT02572284 | Prostate Cancer | Stereotactic Bo... Prostatectomy Quality of Life... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | NCT05406999 | Neoadjuvant The... High Risk Prost... Locally Advance... Intense Endocri... | ADT Abiraterone Ace... Prednisolone ta... Enzalutamide Apalutamide Darotamide Rezvilutamide PARP inhibitor Robot-assisted ... | 18 Years - 80 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer | NCT01088529 | Prostate Cancer | Abiraterone Ace... Prednisone LHRHa | 18 Years - | Cougar Biotechnology, Inc. | |
| Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer | NCT01088529 | Prostate Cancer | Abiraterone Ace... Prednisone LHRHa | 18 Years - | Cougar Biotechnology, Inc. | |
| Safety and Efficacy Study of Hypofractionated Radiotherapy and Androgen Deprivation Therapy for Prostate Cancer | NCT01505075 | Prostate Cancer | Hypofractionate... | 18 Years - | Sunnybrook Health Sciences Centre | |
| Neoadjuvant BKM120 in High-risk Prostate Cancer | NCT01695473 | High Risk Prost... | BKM120 | 18 Years - 85 Years | University of California, San Francisco | |
| Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide | NCT01946165 | Prostate Cancer | Abiraterone Ace... Prednisone Enzalutamide LHRHa | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
